Aurobindo Pharma surpasses Dr Reddy's in FY26 revenue, becoming the second-largest Indian pharma company.
SENSEX 75,495.00
+ 311.64
NIFTY 23,752.85
+ 98.15
CRUDEOIL 9,403.00
Aurobindo Pharma Q4 net up 2% to ₹921 cr
Rahul Shah bullish on pharma, sees Sun Pharma and Aurobindo as key large-cap plays
Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?
Divi’s Labs Q4 net up 13% to ₹751 cr., declares ₹30 dividend
Lilly, AbbVie, J&J, AZ lead an uptick in Big Pharma Q1 growth, with Novo again bringing up the rear
Sun Pharma Q4 Results: Cons profit rises 26% YoY to Rs 2,714 crore; board approves Rs 5/share dividend
Aurobindo Pharma reports a 2% net profit rise to ₹921 crore with total revenue growing 5.6% to ₹8,853 crore in Q4.
Aurobindo Pharma expands its presence in France with the launch of Arrow Pharma Production SAS for generic formulation…
Aurobindo Pharma reports Q4 net profit rise to ₹921 crore, driven by strong European market performance and overall revenue…
During January-March, the company's revenue from operations increased to ₹30,813 crore from ₹29,316 crore recorded in the fourth…
S Chand posts 11% revenue growth in FY26, announces dividend, and anticipates future gains from new curriculum initiatives.
Q4 Results Today, 18th May 2026: Find all the latest Q4 results 2026 updates of 63 Moons Technologies, Afcons Infrastructure,…
